Catalent, Inc. (CTLT) Financials
CTLT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 10.0 billion | 6.3 billion |
2023-09-30 | 10.8 billion | 6.1 billion |
2023-06-30 | 10.8 billion | 6.1 billion |
2023-03-31 | 10.8 billion | 6.1 billion |
CTLT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 18.0 million | 16.0 million |
2023-09-30 | 75.0 million | 19.0 million |
2023-06-30 | 75.0 million | ? |
2023-03-31 | -202.0 million | 6.0 million |
CTLT Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2023-12-31 | -206.0 million |
2023-09-30 | -110.0 million |
2023-06-30 | -86.0 million |
2023-03-31 | -227.0 million |
CTLT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 229.0 million | - | 9.0 million |
2023-09-30 | 280.0 million | - | 11.0 million |
2023-06-30 | 280.0 million | - | 11.0 million |
2023-03-31 | 252.0 million | 4.3 billion | 11.0 million |
CTLT Shares Outstanding
CTLT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 94.0 million | 4.0 million | 250.0 million | - |
2023-09-30 | 128.0 million | 5.0 million | 215.0 million | - |
2023-06-30 | 128.0 million | - | 219.0 million | - |
2023-03-31 | 138.0 million | 4.0 million | 205.0 million | - |
CTLT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 1.0 billion | 853.0 million |
2023-09-30 | 1.1 billion | 833.0 million |
2023-06-30 | 1.1 billion | 833.0 million |
2023-03-31 | 1.0 billion | 857.0 million |
CTLT
Price: $56.50
52 week price:
Earnings Per Share: -7.18 USD
P/E Ratio: -10.11
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 3.0 million
Ebitda: 115.6 millionMarket Capitalization: 10.1 billion